Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
Jennifer R. Brown, John C. Byrd, Paolo Ghia, et al.
Haematologica (2021) Vol. 107, Iss. 6, pp. 1335-1346
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4229-4361
Open Access | Times Cited: 1543
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal - Cardiovascular Imaging (2022) Vol. 23, Iss. 10, pp. e333-e465
Open Access | Times Cited: 209
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia
Cooper Quartermaine, Sanam Ghazi, Aneeq Yasin, et al.
JACC CardioOncology (2023) Vol. 5, Iss. 5, pp. 570-590
Open Access | Times Cited: 44
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
Petra Langerbeins, Can Zhang, Sandra Robrecht, et al.
Blood (2021) Vol. 139, Iss. 2, pp. 177-187
Open Access | Times Cited: 73
Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors
Stefano Molica, David Allsup
Cancers (2025) Vol. 17, Iss. 1, pp. 119-119
Open Access | Times Cited: 1
Guía para el diagnóstico y el tratamiento de la leucemia linfocítica crónica y el linfoma linfocítico de células pequeñas del Grupo Español de Leucemia Linfocítica Crónica (GELLC)
Ángeles Medina, Ana Muntañola, Marta Crespo, et al.
Medicina Clínica (2025)
Closed Access
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies
Sofija Kozarac, Vojin Vuković, Michael G. Fradley, et al.
Blood Reviews (2025), pp. 101268-101268
Closed Access
Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis
Joachim Alexandre, Jonaz Font, Thibault Lenormand, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC)
Ángeles Medina, Ana Muntañola, Marta Crespo, et al.
Medicina Clínica (English Edition) (2025)
Closed Access
Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation
John Alan Gambril, Sanam Ghazi, Stephen Sansoterra, et al.
Leukemia (2024) Vol. 38, Iss. 10, pp. 2141-2149
Open Access | Times Cited: 3
Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents
Andrea Galitzia, Monica Maccaferri, Francesca Romana Mauro, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 1996-1996
Open Access | Times Cited: 2
Cancer and Heart Failure: Dangerous Liaisons
D. Bertolini, Carmine Pizzi, Erwan Donal, et al.
Journal of Cardiovascular Development and Disease (2024) Vol. 11, Iss. 9, pp. 263-263
Open Access | Times Cited: 2
Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors
Yinghong Zhai, Fangyuan Hu, Wentao Shi, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 9, pp. 857-869
Open Access | Times Cited: 6
An integrated approach to cardioprotection in lymphomas
M.V. Maraldo, Mario Levis, Alessandro Andreis, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 6, pp. e445-e454
Open Access | Times Cited: 10
Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis
Ekaterina Proskuriakova, Dhan Bahadur Shrestha, Ranjit Jasaraj, et al.
Clinical Therapeutics (2023) Vol. 46, Iss. 2, pp. 134-145
Closed Access | Times Cited: 5
Selecting initial therapy in CLL
Inhye E. Ahn, Jennifer R. Brown
Hematology (2022) Vol. 2022, Iss. 1, pp. 323-328
Open Access | Times Cited: 8
Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances
Lauren Schaff, Lakshmi Nayak, Christian Grommes
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 7, pp. 882-894
Open Access | Times Cited: 1
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis
Rafael Amorim Belo Nunes, Álvaro Avezum, Mariana de Oliveira Marques, et al.
Annals of Hematology (2024) Vol. 103, Iss. 11, pp. 4613-4620
Open Access | Times Cited: 1
Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors
Nazanin Aghel, Rocío Consuelo Baro Vila, Michelle Lui, et al.
Current Cardiology Reports (2023) Vol. 25, Iss. 9, pp. 941-958
Closed Access | Times Cited: 3
Management of front line chronic lymphocytic leukemia
Nadine Kutsch, Anna Maria Fink, Kirsten Fischer
American Journal of Hematology (2022) Vol. 97, Iss. S2
Open Access | Times Cited: 5
Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada
Rania S. Khelifi, Steven J.T. Huang, Kerry J. Savage, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 6, pp. 1129-1138
Closed Access | Times Cited: 2
Cardiotoxicity in patients treated with acalabrutinib
Petra Langerbeins
Blood (2022) Vol. 140, Iss. 20, pp. 2096-2097
Open Access | Times Cited: 3
Safety of extended pirtobrutinib exposure in relapsed and/or refractory B-cell malignancies
Lindsey E. Roeker, Catherine C. Coombs, Nirav N. Shah, et al.
Acta Haematologica (2024), pp. 1-17
Open Access
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis
Rafael Amorim Belo Nunes, Álvaro Avezum, Mariana de Oliveira Marques, et al.
Research Square (Research Square) (2024)
Open Access
A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)
Sylvain Choquet, Clarisse Marchal, Floriane Deygas, et al.
Annals of Hematology (2024)
Open Access
Page 1 - Next Page

Scroll to top